Gsa Capital Partners LLP Phathom Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 15,083 shares of PHAT stock, worth $95,626. This represents 0.02% of its overall portfolio holdings.
Number of Shares
15,083
Previous 29,406
48.71%
Holding current value
$95,626
Previous $303,000
9.9%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding PHAT
# of Institutions
143Shares Held
74.8MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$64.1 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$47.3 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$44.8 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$26 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$22.2 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $248M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...